| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7297136 | IMPAX | Medicine injection devices and methods |
Jan, 2025
(8 months from now) | |
| US7621891 | IMPAX | Method and apparatus for delivering epinephrine |
Feb, 2025
(9 months from now) | |
Twinject 0.3 is owned by Impax.
Twinject 0.3 contains Epinephrine.
Twinject 0.3 has a total of 2 drug patents out of which 0 drug patents have expired.
Twinject 0.3 was authorised for market use on 25 November, 2009.
Twinject 0.3 is available in injectable;intramuscular, subcutaneous dosage forms.
The generics of Twinject 0.3 are possible to be released after 04 February, 2025.
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 25 November, 2009
Treatment: NA
Dosage: INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
More Information on Dosage
TWINJECT 0.3 family patents
